Measuring the iron content of dopaminergic neurons in substantia nigra with MRI relaxometry

In Parkinson's disease, the depletion of iron-rich dopaminergic neurons in substantia nigra's nigrosome 1 precedes first motor symptoms by two decades. Monitoring this neuronal depletion at an early disease stage is needed for diagnosis and treatment monitoring. Magnetic resonance imaging...

Full description

Saved in:
Bibliographic Details
Published inbioRxiv
Main Authors Brammerloh, Malte, Morawski, Markus, Weigelt, Isabel, Reinert, Tilo, Lange, Charlotte, Pelicon, Primoz, Vavpetic, Primoz, Jankuhn, Steffen, Jaeger, Carsten, Alkemade, Anneke, Balesar, Rawien, Pine, Kerrin, Gavriilidis, Filippos, Trampel, Robert, Reimer, Enrico, Arendt, Thomas, Weiskopf, Nikolaus, Kirilina, Evgeniya
Format Paper
LanguageEnglish
Published Cold Spring Harbor Cold Spring Harbor Laboratory Press 02.07.2020
Subjects
Cell density
Cognitive ability
Dopamine receptors
Iron
Magnetic resonance imaging
Movement disorders
Neurodegeneration
Neurodegenerative diseases
Neuroimaging
Parkinson's disease
Parkinsons disease
Substantia nigra
Online AccessGet full text

Cover

More Information
Summary:In Parkinson's disease, the depletion of iron-rich dopaminergic neurons in substantia nigra's nigrosome 1 precedes first motor symptoms by two decades. Monitoring this neuronal depletion at an early disease stage is needed for diagnosis and treatment monitoring. Magnetic resonance imaging (MRI) is particularly suitable for this task due to its sensitivity to tissue iron. However, the mechanisms of MRI contrast in substantia nigra are not well understood, hindering the development of specific biomarkers. We showed that the dominant contribution to the effective transverse MRI relaxation rate R2* in nigrosome 1 originates from iron accumulated in the neuromelanin of dopaminergic neurons. We linked R2* quantitatively to the product of cell density and local iron concentration in dopaminergic neurons, combining quantitative 3D iron histology, biophysical modeling, and quantitative MRI on post mortem brain tissue. This knowledge opens an avenue for monitoring neuronal iron and density in vivo and may be applied to detect early neurodegeneration in Parkinson's disease. Competing Interest Statement The Max Planck Institute for Human Cognitive and Brain Sciences has an institutional research agreement with Siemens Healthcare. NW was a speaker at an event organized by Siemens Healthcare and was reimbursed for the travel expenses.
DOI:10.1101/2020.07.01.170563